BLTE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsBLTE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
Belite Bio Advances Novel Retinal Disease Treatment
Premium
Company Announcements
Belite Bio Advances Novel Retinal Disease Treatment
1M ago
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Premium
Press Releases
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
1M ago
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
PremiumPress ReleasesBelite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
3M ago
Belite Bio Advances Retinal Disease Treatment
Premium
Company Announcements
Belite Bio Advances Retinal Disease Treatment
4M ago
Belite Bio reports Q1 EPS (33c), consensus (28c)
Premium
The Fly
Belite Bio reports Q1 EPS (33c), consensus (28c)
4M ago
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
PremiumPress ReleasesBelite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
4M ago
Belite Bio presents additional analysis from Phase 2 study of tinlarebant
Premium
The Fly
Belite Bio presents additional analysis from Phase 2 study of tinlarebant
5M ago
Belite Bio to participate on KOL Webinar to discuss STGD1, GA
Premium
The Fly
Belite Bio to participate on KOL Webinar to discuss STGD1, GA
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100